Carcinogenesis data for 315 chemicals were obtained from the National Cancer Institute-National Toxicology Program (NCI-NTP) bioassay programs and were analyzed to examine the shape ofcarcinogenesis dose-response curves. Tumor site data were more often consistent with a quadratic response than with a linear response, suggesting that the routine use of linear dose-response models will often overestimate risk. Information from in vivo short-term mutagenicity and genotoxicity assays was also obtained for most ofthese rodent biossanys. It was found that there were no clear relationships between the shape ofthe carcinogenesis dose-response curve and the result ofthe short-term test. These observations argue against the concept that carcinogens that are positive in a short-term assay be regulated usinga linear dose-response curve and those that are negative be regulated using a sublinear dose-response curve or a safety factor approach.
Introduction
One of the more controversial issues in chemical carcinogenesis is that of estimating low-dose effects (1) (2) (3) (4) (5) (6) (7) . Because of sample size considerations, experimental data must be obtained at relatively high exposure levels and then necessarily extrapolated to relatively low human exposure levels (5) (6) (7) . Although the basic mechanisms of carcinogenicity are not well understood, it is believed that the process is multistage (2, (8) (9) (10) (11) (12) (13) . Ifthis is the case, a dose-response curve for a carcinogen would expectably depend on the transition between particular stages or the clonal expansion of cells in a particular stage that the chemical affects (1, 2, 4, (11) (12) (13) (14) (15) (16) . For example, the first stage is thought to involve mutational changes in the DNA as a result of what is believed to be a linear-in-dose genotoxic effect of the chemical (1, 2, 4, 11, 12, 15) . Chemical promoters can enhance the expansion of these mutated cells by a selective growth process that is generally assumed to be nonlinear (1, 2, 4, 11, 12, 15) . Later steps, such as progression, can also be chemically dependent with both linear and nonlinear dose-response relationships (12, 15, 17) . Note also that the chemical itself can undergo metabolic changes that may lead to a nonlinear relationship between the administered chemical and the effective metabolite that induces carcinogenesis (3, 18) .
Accurate determination of the shape of the dose-response curve is critical to predicting low-dose risks. Some doseresponse models have the property that they are "low-dose linear," or "linear" for short (4) . A linear dose-response model is a model in which the slope of the dose-response curve evalu-ated at dose zero is positive and proportional to dose. One such model is the one-hit/one-stage model. Other models exhibit curvature for which the slope ofthe dose-response curve is equal to zero at dose zero. The two-hit/one-stage or quadratic model is an example of such a model. Finally, some models exhibit curvature that is greater than linear in the low-dose range. A model that typifies this type of response is the square-root model. The mathematical descriptions of these models are given in the Methods section. These three simple models (square-root, linear, and quadratic) include the three types of qualitative behavior most frequently considered in carcinogenesis studies (e.g., supralinear dose response, linear dose response, and sublinear dose response).
In examining experimental carcinogenesis data from a public health standpoint, we find that a dose-response function that is linear in low doses will typically fit the observed data and will usually overestimate the observed carcinogenic risk at the lowdose level. Thus, the linear model is considered to be a conservative model. However, it is important to determine the actual degree to which the linear model is conservative. One approach to evaluating linearity versus nonlinearity is to examine the available animal data. In this paper we focus on two questions: a) What is the usual shape ofthe dose-response curve for carcinogenic response to environmental agents? and b) Do short-term in vitro genotoxicity assays predict the shape of these doseresponse curves? To answer these questions, we have analyzed data from the NCI/NTP 2-year rodent carcinogenesis studies and from in vitro assays for mutagenicity and genotoxicity.
Data and Statistical Methods
In any analysis ofcarcinogenesis data, one is faced with the difficulties ofdealing with small sample sizes. The carcinogenesis data generated from these small samples are often consistent with many different dose-response functions, including a linear ¶hble 1. Combinations of primary tumor sites.
All squamous cell and basal cell papillomas, adenomas, and carcinomas ofthe skin All fibroma and fibrosarcoma of the subcutaneous tissue Alveolar bronchiolar adenomas and carcinomas of the lung All nasal cavity tumors All hematopoietic system tumors All circulatory system tumors Adenomas/nodules and carcinomas of the liver Adenomas and adenocarcinomas of the tubular cells of the kidney Papillomas and carcinomas of the transitional cells of the kidney All urinary bladder tumors All pituitary tumors All pheochromocytomas of the adrenal gland Adenomas and carcinomas of the adrenal cortex Adenomas and carcinomas of the thyroid C-cells Adenomas and carcinomas of the thyroid follicular cells All tumors of the parathyroid Adenomas and carcinomas of the pancreas islet cells Squamous cell papilloma and carcinoma of the forestomach All tumors of the mammary gland Interstitial cell tumors of the testis Endometrial stromal polyps and sarcomas of the uterus All tumors of the zymbal gland All mesothelioma dose-response function. However, one could just as easily test to see whether the data are consistent with a particular nonlinear hypothesis, such as a quadratic dose-response function. Because ofthe small sample sizes, one finds that the data will also be consistent with several nonlinear dose-response functions (19) . We are interested in the degree to which carcinogenicity data are actually consistent with linearity and whether other possible doseresponse functions may be more appropriate.
Our analysis is based on tumorigenicity data from 344 rodent bioassays on 315 chemicals studied by the NCI and the NTP (20, 21) . For 
was fit to all cancer sites using the survival-adjusted quantal response (23, 24) , where ( 
Results
In Vivo Dose-Response Shape Table 2 summarizes the results of our analysis of the routine shapes ofdose-response curves. In Table 2 (part A) we see that 67% (260/390) ofthe experimental results are consistent with all three ofthe models and 84% (326/390) are consistent with two or more models. It is clear that the linear model fits most of the data (327/390) and that all three models fit much ofit. If we look at the model that best fits the experimental data without regard to the adequacy ofthis fit ( (28) (29) (30) (31) and that nongenotoxic compounds will result in threshold or nonlinear dose response. The belief that genotoxic agents induce linear dose response stems from theoretical arguments about one molecule of a genotoxic compound interacting with DNA resulting in a "single hit." The probability of cancer is then assumed to be proportional to the number of "hits" resulting in a linear, no-threshold dose-response model. The nonlinear shape for nongenotoxic compounds is based on mechanistic arguments concerning cytotoxicity, and promotion, mechanisms that are generally thought to be threshold mediated or nonlinear. We are interested in whether the carcinogenicity data support this theory. Although it would be difficult to reject or accept it on the basis ofbioassay data, with a data base this large, we should at least see shape patterns that conform to this theory.
To evaluate the relationship between genotoxicity and doseresponse shape, we repeated the analysis ofthe previous section, stratifying chemicals into those that are mutagenic using the Ames Salmonella assay and those that are not. A chemical was labeled as a positive mutagen if it was positive in any of the various Salmonella assays conducted by the NTP (32) . Table 3 illustrates the results. There were 367 sex-by-species-bychemical groups (Table 3 , case A) for which the carcinogenesis response was significant at the 1 % level (p< 0.01); 230 (63%) were positive in the Salmonella assay, and 137 (37%) were negative. Most of the sites adequately fit all three of the doseresponse models, with 65% (150/230) of the mutagenic compounds fitting all three models, and 67% (92/137) fitting all (35, 36) , to presume that knowledge ofthe presence or absence ofchemical effects on one process (DNA damage) is sufficient to explain doseresponse shape is naive. All of this is not to say that linear low-dose extrapolation is not the best policy from a public health standpoint. However, the study results imply that using linear risk estimation may lead to risks that often are overestimated based the experimental data. Although the carcinogenesis data suggest nonlinearity more often than linearity, they make no statement about the presence or absence of threshold levels. With simple, nonlinear kinetic models, one still obtains linearity of response at low-dose levels (3) . For purposes of low-dose risk estimation and determination ofdose-response relationships, dose-response information from other systems such as DNA adduct formation, toxicokinetics, and cellular proliferation should be coupled with the carcinogenesis data for low-dose risk estimation. This approach to carcinogenic risk estimation would incorporate biologically pertinent and measurable parameters into the uncertain and politically volatile business of public health management of chemical carcinogens.
